Calcium plays a role in blood pressure (BP) regulation, but the importance of supplemental calcium intake for the prevention of hypertension is still debated. We conducted a meta-analysis of randomized controlled trials to determine the effect of calcium supplementation on BP. A systematic search for randomized trials of calcium supplementation and BP in non-pregnant subjects was performed in Medline from 1966 to June 2003. Seventy-one trials were identified, 40 of which met the criteria for meta-analysis (total of 2492 subjects). Two persons independently extracted data from original publications on changes in calcium intake and BP. In addition, data were collected on subjects' characteristics, that is, age, gender, initial BP and initial calcium intake. A random effects model was used to obtain the effect of calcium supplementation on BP, overall and in predefined population subgroups. Calcium supplementation (mean daily dose: 1200 mg) reduced systolic BP by À1.86 mm Hg (95% confidence interval: À2.91 to À0.81) and diastolic BP by À0.99 mm Hg (À1.61 to À0.37). In people with a relatively low calcium intake (p800 mg per day) somewhat larger BP estimates were obtained, that is, À2.63 (À4.03 to À1.24) for systolic BP and À1.30 (À2.13 to À0.47) for diastolic BP. Our study suggests that an adequate intake of calcium should be recommended for the prevention of hypertension. More research on BP in people with calcium-deficient diets is warranted.
Introduction
High blood pressure (BP) is a well-established risk factor for cardiovascular morbidity and mortality. 1 Calcium is a key factor in the regulation of cardiovascular function and alterations in calcium metabolism have been reported in human and experimental hypertension. 2 Epidemiological studies have shown an association between calcium intake and BP, but findings are inconsistent and could be confounded by healthy lifestyle and diet. 3 Randomized controlled trials (RCTs) that provide stronger evidence for causality suggest that supplemental calcium could indeed exert an effect on BP, but reductions are generally small. [4] [5] [6] Because of heterogeneity in BP response among subjects, however, it cannot be excluded that an adequate intake of calcium is important for the prevention of hypertension in specific populations or population subgroups. [7] [8] [9] [10] [11] [12] We performed an updated metaanalysis of randomized controlled trials of calcium supplementation and BP, which had sufficient power to detect small treatment effects with high precision. Furthermore, we performed meta-analyses in strata of subject characteristics to examine in more detail heterogeneity of BP response to calcium intake.
Subjects and methods

Search strategy
The MEDLINE database (1966 ( -June 2003 was searched for RCTs of calcium supplementation and BP using the terms '(calcium NOT calcium antagonis* NOT calcium channel NOT calcium entry NOT calcium blocker) AND (blood pressure OR hypertension)' as Medical Subject Headings (MESH terms) or words in title. Searches were limited to clinical trials or randomized controlled trials in humans. Furthermore we performed a manual search using citation lists from retrieved articles, meta-analyses and systematic reviews to identify other eligible studies. No language restriction was used.
Selection of trials
Randomized controlled trials on the effect of calcium supplementation on BP in non-pregnant normotensive or hypertensive subjects were selected. Studies were excluded if they met any of the following criteria: data included in prior reports (duplicate publication), lack of appropriate BP data, co-intervention (except for co-intervention with vitamin D), study population with renal disease or hyperparathyroidism, lack of control group or study duration of less than 2 weeks. Seventy-one RCTs were identified (reference list of all identified studies is available from the authors), of which 40 proved eligible for this meta-analysis ( Figure 1 ).
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Validity assessment and data abstraction We retrieved original articles for data abstraction, except for two trials for which only an abstract was available. 33, 47 Two authors (LAJM and JMG) independently extracted the data. In case of discrepancies consensus was reached, if necessary with the help of a third author (MTS). Studies were scored with regard to blinding towards the type of treatment (i.e. open, single-blind, double-blind).
Extraction of study characteristics
Changes in systolic and diastolic BP and accessory variance measures were abstracted from articles, as were data on calcium dose and the following trial population characteristics: mean age, gender distribution, race initial systolic and diastolic BP and initial (i.e. habitual) calcium intake. One trial tested different doses of calcium with a single control group 34 and three trials tested multiple formulations of calcium with a single control group. 32, 33, 46 For these trials, BP changes in the intervention groups were averaged and extracted from BP change in the control group. In trials in which BP was measured at several points in time, we used the longest followup period during which the patients were still on randomized treatment. With regard to BP, measurements in sitting position were used. If not available, supine BP, standing BP or mean daytime ambulatory BP was taken in that order. For one trial, we used BP data that were adjusted for confounders, because raw data were not given in the original article. 28 If different publications on identical studies were found, we used all available information for data abstraction and cited the most recent publication. 34, 52 One trial in which all subjects participated in the parallel phase and part of the subjects in a crossover phase was treated as if it had a parallel design. 50 Imputations were made for mean age, based on the midpoint of the age range, in one trial, 24 gender (i.e. 50% males) in three trials 18, 24, 47 and initial calcium intake in 16 trials. The latter imputation was based on the mean calcium intake in the population from which trial participants had been recruited, for which data were derived from population-based dietary surveys (overview of surveys and mean population calcium intakes is available from the authors). If participants had been on a run-in diet for more than 4 weeks before the start of the trial, calcium intake during that period was taken as the habitual calcium intake. 38, 42 For one trial, we contacted the authors to obtain additional data. 26 For two other trials, 24, 47 we derived data from a meta-analysis 6 and a review, 9 respectively.
Meta-analysis
For parallel trials, the change in BP from baseline in the intervention group was subtracted from the change in BP from baseline in the control group to yield the net change in BP owing to calcium supplementation. For crossover trials with similar baseline BP for intervention and control periods, the net change in BP was calculated as the final BP during intervention minus the final BP during control treatment. RCTs excluded, with reason 1. data from the same patients included in prior reports (n = 6) 2. lack of appropriate blood pressure data (n = 3) 3. co-intervention (n = 13) 4. study population with renal disease or hyperparathyriodism (n = 2) 5. non-placebo-control group (n = 1) 6. duration < 2 weeks ( n = 6) RCTs excluded, with reason 1. no RCT (n = 10) 2. pregnant study population ( n = 3) Figure 1 Selection of studies for meta-analysis of randomized controlled trials of calcium supplementation and blood pressure. change in BP in intervention and control groups or intervention and control periods (crossover design). For parallel trials in which no variance measures for paired differences were given the pooled variance was estimated according to the method of Follmann et al. 53 assuming a correlation of 0.50 between baseline and final BP values. If variance measures were only reported at baseline, we assumed similar variance at the end of followup. The SAS statistical package was used for dataanalysis (SAS Version eight, SAS Institute, Inc., Cary, NC, USA). Homogeneity of effect size was tested by Q statistics 54 and significant heterogeneity was found among trials (Po0.0001) both for systolic BP (w 2 ¼ 308.16) and diastolic BP (w 2 ¼ 334.12). We chose a random-effects model for meta-analysis of continuous outcomes that takes into account both within and between study variations, using the SAS PROC MIXED statement. 55 For each trial, the BP effect was weighted by the reciprocal of its variance, that is, 1/SE 2 . BP estimates are reported with 95% confidence intervals. Two-sided P-values o0.05 were considered statistically significant.
We performed predefined subgroup analyses to study modification of BP response to calcium supplementation. Subgroups were based on calcium dose (p1000 mg vs 41000 mg/day) and trial population characteristics, that is, Median age (o45 vs X45 years), initial BP (o140/90 vs X140/ 90 mm Hg), gender (p50 vs 450% males) and initial calcium intake (o800 vs X800 mg/day). Analysis by calcium dose, age and initial calcium intake were based on the median of the frequency distribution of these variables.
Analyses in strata of trial population characteristics and calcium dose were repeated using a multivariate random effects model adjusting for potential confounders (except when used as a stratification variable), that is, mean age (years), gender distribution (% males), initial BP (dichotomous variable, i.e. o140/90 vs X140/90 mm Hg), initial calcium intake (mg/day) and calcium dose (mg/day).
Publication bias was visually examined after construction of a funnel plot in which weight factors (1/ SE 2 ) were plotted against net changes in systolic BP. In addition a non-parametric 'trim and fill' method was used to adjust for publication bias. 56 Table 1 displays characteristics of 40 trials selected for meta-analysis, comprising 50 different strata and a total of 2492 subjects. Eighteen strata had a crossover design (572 subjects in total) and 32 were double-blind. Trial sample size ranged from 7 to 452 subjects. Duration of intervention ranged from 3 to 208 weeks (median: 9.5 weeks) and daily calcium dose from 355 to 2000 mg (mean: 1200 mg, median: 1055 mg). In four trials, calcium intake was increased by dietary intervention 14, 21, 22, 26 and in one trial both by dietary intervention and calcium supplements. 33 Trials were mainly conducted in white populations (39 strata), and mostly included both men and women (31 strata). Mean age of trial populations ranged from 11 to 77 years (43.7714.3 years (mean7s.d.)). Based on mean BP at baseline (cutoff: 140/90 mm Hg), 27 strata were derived from normotensive populations and 23 strata from hypertensive populations. From visual examination of the funnel plot it was concluded that small trials with large systolic BP reductions are possibly overrepresented ( Figure 2) . A non-parametric 'trim and fill' method revealed that two trials might have been missing. After adjustment for putative missing data, the overall effect on systolic BP was attenuated to À1.33 mm Hg (95% confidence interval (CI) À2.66 to 0.00).
Results
Study characteristics
Quantitative data analysis Forest plots of BP effects in individual trials with 95% CIs are shown in Figure 3 . Meta-analysis of randomized controlled trials yielded a weighted estimate for the overall effect of calcium supplementation of À1.86 mm Hg (À2.91 to À0.81) on systolic BP and of À0.99 mm Hg (À1.61 to À0.37) on diastolic BP. If only double-blind trials were included, reductions were À1.67 mm Hg (À2.87 to À0.47) and À0.93 mm Hg (À1.64 to À0.22), respectively. BP estimates were not significantly different among subgroups (Table 2) , but there was a tendency towards an increased BP sensitivity to calcium in populations with a low initial calcium intake (p800 mg/day) compared to populations with higher intakes (4800 mg/day), both for systolic BP (À2.68 mm Hg (À4.07 to À1. 28 Multivariate, stratified meta-analysis (Table 2 ) with adjustment for subgroup differences in mean age, gender distribution, initial BP, initial calcium intake and calcium dose, yielded essentially similar results. BP response did not differ among subgroups, but again a tendency towards larger BP reductions was observed in populations with a low initial calcium intake (p800 mg/day) which could not be explained by differences in mean age, gender distribution, initial BP or calcium dose.
Discussion
This meta-analysis of 40 RCTs shows that calcium supplementation (B1 g/day) may significantly reduce systolic BP by 1.9 mm Hg and diastolic BP by 1.0 mm Hg. The BP effect tended to be more pronounced in populations with a habitually low calcium intake (2.6/1.3 mm Hg). Blood pressure showed no further decrease when calcium doses exceeded 1 g/day.
Compared to previous meta-analyses of calcium and BP, this study included six RCTs 2,16,19,22,30,37 that had not been analysed previously. A random effects model was used to account for heterogeneity, using an advanced statistical approach. 55 Power of this meta-analysis was sufficient to allow subgroup analyses to study modification of BP response to calcium supplementation. Our pooled BP estimate of À1.9/À1.0 mm Hg was somewhat larger than in previous meta-analyses of calcium supplementation trials (ranging from À1.4 to À0.8 mm Hg systolic and À0.8 to À0.2 mm Hg diastolic). [4] [5] [6] If only doubleblind trials with high internal validity were included in meta-analysis, our pooled BP estimate was slightly attenuated to À1.7/À0.9 mm Hg.
It has been suggested supplemental calcium exerts a stronger effect on BP in calcium-deficient subjects. 5, 11, 57 In our meta-analysis, BP response to 44 Thomsen 1987 calcium tended to be stronger in people with a low habitual calcium intake (À2.7/À1.3 mm Hg) compared to people with a higher intake (À0.9/ À0.6 mm Hg). However, it should be noted that initial calcium intake was not reported in 16 trials, for which we imputed the mean intake of the population from which subjects were recruited. These findings should therefore be interpreted with caution. Previous meta-analyses showed stronger associations of calcium with BP in hypertensive subjects, 4 at high doses of calcium 58 and for foodbased increases in calcium intake. 6 This could not be confirmed in our study, except for a potentially larger effect of calcium-enriched foods on systolic BP. Stratified analysis of dietary compared to supplemental calcium, however, included only five dietary intervention studies and may have lacked power.
High intake of calcium is often accompanied by an increased intake of other nutrients, including saturated fat and sodium, which may elevate BP. In the Dietary Approaches to Stop Hypertension (DASH) trial, the effect of dietary patterns on BP was assessed. 59 The DASH combination diet, rich in fruits, vegetables and low-fat dairy products, reduced systolic and diastolic BP to a greater extent Prospective cohort studies provide better insight into the long-term BP effect of calcium intake than trials, that are mostly of short duration. However, observational data must be interpreted with caution because of inaccuracies in the assessment of habitual calcium intake, potential confounding by other dietary and lifestyle factors and the fact that the range of calcium intake within a single population may be too limited to demonstrate an effect on BP. In the Third National Health and Nutrition Examination Survey (NHANES III), a higher intake of calcium was associated with a reduced rate of rise in systolic BP with age, suggesting an effect of dietary calcium also on long-term BP control. 60 Minor reductions in population BP could have a substantial impact on cardiovascular disease in westernized societies. MacMahon et al. 61 showed that a prolonged difference in usual diastolic BP of only 5 mm Hg is associated with at least 34% less stroke and 21% less coronary heart disease. This meta-analysis showed a small favourable effect of calcium supplementation on BP. This beneficial effect may be larger in populations with a habitually low calcium intake, for example in Asian subjects. We recommend that more research is carried out on the potential health benefits of increased calcium intake, especially in vulnerable subgroups. 
